ADC Therapeutics (ADCT) Receivables - Net (2021 - 2026)
ADC Therapeutics has reported Receivables - Net over the past 6 years, most recently at $31.0 million for Q1 2026.
- Quarterly results put Receivables - Net at $31.0 million for Q1 2026, down 2.26% from a year ago — trailing twelve months through Mar 2026 was $31.0 million (down 2.26% YoY), and the annual figure for FY2025 was $29.1 million, up 43.32%.
- Receivables - Net reached $31.0 million in Q1 2026 per ADCT's latest filing, up from $29.1 million in the prior quarter.
- Across five years, Receivables - Net topped out at $48.0 million in Q4 2022 and bottomed at $26752.0 in Q1 2022.
- Median Receivables - Net over the past 5 years was $23.9 million (2023), compared with a mean of $24.6 million.
- The largest annual shift saw Receivables - Net skyrocketed 1003411.3% in 2022 before it crashed 47.52% in 2023.
- Over 5 years, Receivables - Net stood at $48.0 million in 2022, then plummeted by 47.52% to $25.2 million in 2023, then dropped by 19.32% to $20.3 million in 2024, then surged by 43.32% to $29.1 million in 2025, then increased by 6.62% to $31.0 million in 2026.
- Business Quant data shows Receivables - Net for ADCT at $31.0 million in Q1 2026, $29.1 million in Q4 2025, and $22.9 million in Q3 2025.